Prescient Therapeutics Ltd (PTX)

Sydney
0.195
+0.015(+8.33%)
  • Volume:
    7,250,210
  • Bid/Ask:
    0.185/0.195
  • Day's Range:
    0.175 - 0.198

PTX Overview

Prev. Close
0.18
Day's Range
0.175-0.198
Revenue
70K
Open
0.18
52 wk Range
0.054-0.285
EPS
-0.01
Volume
7,250,210
Market Cap
124.91M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
5,845,649
P/E Ratio
-
Beta
1.89
1-Year Change
254.55%
Shares Outstanding
640,553,010
Next Earnings Date
-
What is your sentiment on Prescient Therapeutics Ltd?
or
Market is currently closed. Voting is open during market hours.

Prescient Therapeutics Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuySellBuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyNeutralNeutralStrong Buy

Prescient Therapeutics Ltd Company Profile

Prescient Therapeutics Ltd Company Profile

Employees
3
Market
Australia

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.

Read More
  • out for now
    0
    • Looking good
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.